Figure 5. LOX controls EGF-dependent cell proliferation in vitro and tumour growth in vivo.

(a,b) Graphs showing cell proliferation in control (shCtl) and LOX-depleted (shLOX A,B) MDA-MB-231 (a) and U87 (b) cells grown in 10% FBS (serum) or serum-free medium (serum free) and treated with PBS, rhMATN2 (500 ng ml⁻¹) and EGF (50 ng ml⁻¹) as indicated. All data are represented as mean±s.d. from four independent experiments. **P<0.01, Student's t-test. (c) Kaplan–Meier survival plot for mice following tail vein injection of control (shCtl) or LOX-depleted (shLOX A) MDA-MB-231 cells. Seven mice were used in each group. (d) H&E staining of lungs from mice in c. Scale bar, 500 μm. (e) Quantification of lung deposits in mice. Data is represented as mean±s.d. from seven samples. **P<0.05, Mann–Whitney analysis. (f) Photomicrographs for MATN2 (red) and EGFR (green) in lung deposits. Scale bar, 10 μm. (g) Quantification of samples in f. Data is represented as mean±s.e.m. from six samples. **P<0.01, Student's t-test.